What is PneumaCare?
Based in Cambridge, PneumaCare Ltd is a pioneer in the development of Structured Light Plethysmography (SLP) technology. The company provides a suite of sophisticated tools, including the Thora-3Di systems and PneumaView 3D, which facilitate non-contact and non-aerosol generating lung function assessment. By eliminating the need for invasive procedures, PneumaCare addresses critical gaps in both pediatric and adult respiratory medicine. Their platform is engineered to provide real-time, high-fidelity monitoring, thereby streamlining diagnostic pathways for healthcare providers and clinical researchers globally. The company's commitment to non-invasive imaging positions it as a key player in the modernization of respiratory health management.
How much funding has PneumaCare raised?
PneumaCare has raised a total of $1.6M across 1 funding round:
Unspecified
$1.6M
Unspecified (2013): $1.6M with participation from Cambridge Angels
Key Investors in PneumaCare
Cambridge Angels
A prominent UK-based business angel network comprised of experienced entrepreneurs who provide smart capital and mentorship to high-growth ventures in the technology and healthcare sectors.
What's next for PneumaCare?
With this major enterprise-level funding, PneumaCare is well-positioned to scale its operational footprint and expand the clinical adoption of its SLP systems. The strategic roadmap likely involves deepening market penetration within hospital networks and research institutions that prioritize patient comfort and diagnostic precision. As the company moves beyond its initial development phase, the focus will shift toward enhancing the PneumaView 3D software ecosystem and potentially exploring new applications for its proprietary imaging technology. By leveraging this capital, PneumaCare aims to set a new standard for respiratory monitoring, ensuring that clinicians have access to actionable data without the limitations of traditional, contact-based diagnostic methods.
See full PneumaCare company page
